Cargando…

Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide

Tuberous sclerosis complex (TSC) is a genetic disorder characterised by highly variable comorbid dysfunction and subsequent morbidity. The mTOR inhibitor everolimus is indicated for the treatment of adult TSC patients with renal angiomyolipomas (AMLs) and for subependymal giant astrocytoma (SEGA) in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davies, Mark, Saxena, Anurag, Kingswood, John C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5311836/ https://www.ncbi.nlm.nih.gov/pubmed/28202028 http://dx.doi.org/10.1186/s13023-017-0581-9

Ejemplares similares

Adverse Events of Everolimus in Patients with Tuberous Sclerosis Complex Treated for Renal Angiomyolipoma/Subependymal Giant Cell Astrocytoma
por: Gau, Shuo-Yan, et al.
Publicado: (2023)

Pooled analysis of menstrual irregularities from three major clinical studies evaluating everolimus for the treatment of tuberous sclerosis complex
por: Sparagana, Steven, et al.
Publicado: (2017)

Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2
por: Bissler, John J, et al.
Publicado: (2019)

Real-World Evidence Study on the Long-Term Safety of Everolimus in Patients With Tuberous Sclerosis Complex: Final Analysis Results
por: Ruiz-Falcó Rojas, María Luz, et al.
Publicado: (2022)

Everolimus for treatment of tuberous sclerosis complex‐associated neuropsychiatric disorders
por: Krueger, Darcy A., et al.
Publicado: (2017)

Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study
por: Bissler, John J., et al.
Publicado: (2017)

Everolimus dosing recommendations for tuberous sclerosis complex–associated refractory seizures
por: Franz, David N., et al.
Publicado: (2018)

TuberOus SClerosis registry to increAse disease awareness (TOSCA) Post-Authorisation Safety Study of Everolimus in Patients With Tuberous Sclerosis Complex
por: Kingswood, J. Chris, et al.
Publicado: (2021)

The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma
por: Bissler, John J., et al.
Publicado: (2017)

Everolimus induced organizing pneumonia in a patient with tuberous sclerosis complex
por: Lanfranco, Julio, et al.
Publicado: (2021)

Effect of everolimus on multifocal micronodular pneumocyte hyperplasia in tuberous sclerosis complex
por: Daccord, Cécile, et al.
Publicado: (2020)

Effectiveness and safety of everolimus treatment in patients with tuberous sclerosis complex in real-world clinical practice
por: Cockerell, Ine, et al.
Publicado: (2023)

The use of everolimus in the treatment of neurocognitive problems in tuberous sclerosis (TRON): study protocol for a randomised controlled trial
por: Randell, Elizabeth, et al.
Publicado: (2016)

Everolimus and intensive behavioral therapy in an adolescent with tuberous sclerosis complex and severe behavior()()()
por: Gipson, Tanjala T., et al.
Publicado: (2013)

Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): current perspectives
por: Overwater, Iris E, et al.
Publicado: (2019)

Sequential everolimus for angiomyolipoma associated with tuberous sclerosis complex: a prospective cohort study
por: Gu, Liangyou, et al.
Publicado: (2021)

Low-Dose Everolimus Maintenance Therapy for Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex
por: Luo, Cong, et al.
Publicado: (2021)

The Effect of Everolimus on Subependymal Giant Cell Astrocytoma (SEGA) in Children with Tuberous Sclerosis Complex
por: BAKHTIARY, Hassan, et al.
Publicado: (2021)

Resolution of multifocal micronodular pneumocyte hyperplasia with everolimus in a patient with tuberous sclerosis complex
por: Shoji, Tetsuaki, et al.
Publicado: (2021)

Stick or twist: Everolimus for seizures in tuberous sclerosis complex during the COVID-19 pandemic
por: Moloney, Patrick B., et al.
Publicado: (2021)

Profile of everolimus in the treatment of tuberous sclerosis complex: an evidence-based review of its place in therapy
por: Capal, Jamie K, et al.
Publicado: (2016)

Pilot study evaluating everolimus molecular mechanisms in tuberous sclerosis complex and focal cortical dysplasia
por: Leitner, Dominique F., et al.
Publicado: (2022)

Mutational analysis of renal angiomyolipoma associated with tuberous sclerosis complex and the outcome of short-term everolimus therapy
por: Ni, Jianxin, et al.
Publicado: (2019)

Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis
por: Bissler, John J., et al.
Publicado: (2018)

Fibrous Plaque of the Eyelid in a Patient with Tuberous Sclerosis Responding to Everolimus
por: Park, Sung-Min, et al.
Publicado: (2018)

Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex
por: Franz, David Neal
Publicado: (2013)

EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex
por: Fogarasi, Andras, et al.
Publicado: (2016)

Everolimus safety and efficacy for renal angiomyolipomas associated with tuberous sclerosis complex: a Spanish expanded access trial
por: Robles, Nicolás Roberto, et al.
Publicado: (2016)

Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial
por: Cai, Yi, et al.
Publicado: (2018)

Everolimus versus sirolimus for angiomyolipoma associated with tuberous sclerosis complex: a multi-institutional retrospective study in China
por: Luo, Cong, et al.
Publicado: (2021)

Erratum: Fibrous Plaque of the Eyelid in a Patient with Tuberous Sclerosis Responding to Everolimus
por: Park, Sung-Min, et al.
Publicado: (2018)

Effect and Complications of Everolimus Use for Giant Cardiac Rhabdomyomas with Neonatal Tuberous Sclerosis
por: Shibata, Yuka, et al.
Publicado: (2019)

Challenges in the management of a case of tuberous sclerosis
por: Rathi, Anubhav, et al.
Publicado: (2012)

Use of the mTOR inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy
por: Wheless, James W.
Publicado: (2015)

Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study
por: Franz, David N., et al.
Publicado: (2016)

Observational study of characteristics and clinical outcomes of Dutch patients with tuberous sclerosis complex and renal angiomyolipoma treated with everolimus
por: Zonnenberg, Bernard A., et al.
Publicado: (2018)

Persistent Hepatitis E Infection in a Patient with Tuberous Sclerosis Complex Treated with Everolimus: A Case Report
por: van Dijk, Wobke E. M., et al.
Publicado: (2017)

Efficacy, Retention and Tolerability of Everolimus in Patients with Tuberous Sclerosis Complex: A Survey-Based Study on Patients’ Perspectives
por: Willems, Laurent M., et al.
Publicado: (2021)

Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation–associated metastatic renal-cell carcinoma
por: Alsidawi, Samer, et al.
Publicado: (2018)

Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference
por: Krueger, Darcy A., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_j22bhtphvgoar30tshkmf7a648